Lytix Biopharma’s preclinical activity moves into OCCI
Prime Minister Erna Solberg officially opened Oslo Cancer Cluster Innovation Park (OCCI) on August 24 2015. The building houses around 20 companies related to cancer research and drug development. The Radium Hospital OUS and the Institute of Cancer Research are the closest neighbors. By integrating research and innovation, OCCI will become one of Europe's leading centers for private and public research collaboration - for the benefit of future cancer patients.
Karita Bekkemellem, CEO in Norwegian Pharma Industry, stated that the opening speech Prime Minister Erna Solberg held could be historic.
'Norwegian cancer patients should not have to wait long for new treatment options, and they will gain increased access to experimental therapy. Norwegian-based pharmaceutical industry can create new jobs and lead to health growth in Norway. Private and public partnerships must be established. Such political leadership enables us to save more patients in the future.'
Øystein Rekdal, Lytix Biopharma’s Chief Scientific Officer, says the following about Lytix Biopharma in OCCI:
'With the opening of OCCI, Oslo Cancer Cluster will further strengthen its position in international oncology drug development. For Lytix Biopharma it is important to be present at OCCI where the opportunities for closer cooperation with academia in Norway and abroad will be increased. By establishing our own research activities in OCCI we open for closer cooperation with the immune oncology community.'
Senior researcher Baldur Sveinbjørnsson, CEO Unni Hjelmaas and Chief Scientific Officer Øystein Rekdal at the opening of OCCI
The Norwegian press was present at the opening. Find links to some of the articles and interviews here (only in Norwegian):